GHRP-6: Published Research

Introduction

GHRP-6 (His-(D-Trp)-Ala-Trp-(D-Phe)-Lys-NH2) has been the subject of published scientific research spanning more than four decades. The literature encompasses receptor pharmacology, pharmacokinetic characterization, and a substantial body of animal model studies examining cardiovascular, hepatic, dermal, and other tissue contexts. This article provides a neutral bibliographic summary of selected peer-reviewed studies, with methodology and findings attributed to their respective authors. No conclusions are drawn in SpartaLabs' voice regarding efficacy or safety in humans. The molecular pharmacology underlying these observations is covered separately in the GHRP-6 mechanism of action article.

Methodology Types in the Published Literature

Published GHRP-6 research falls into several methodological categories:

In vitro cell culture studies have been used to characterize receptor binding, intracellular signaling cascades, and direct cellular effects in isolated pituitary somatotrophs, cardiac cells, hepatic stellate cells, and fibroblast preparations.

Rodent in vivo models represent the majority of the preclinical pharmacology literature. Studies have employed surgically induced ischemia-reperfusion injury models, chemical hepatotoxicity models (carbon tetrachloride, bile duct ligation), and wound excision models in rats and mice.

Large animal models — including porcine cardiovascular ischemia preparations — have appeared in the literature, providing intermediate translational context between rodent studies and human biology.

Human pharmacokinetic data are available from a published study conducted in healthy male volunteers, described in detail below.

Summary of Published Studies

Foundational Pharmacology: Bowers et al. (1984)

The foundational characterization of GHRP-6 was published by Bowers, Momany, Reynolds, and Hong in Endocrinology in 1984 (PMID: 6714155) [1]. The authors described a systematic in vitro and in vivo pharmacological evaluation of the hexapeptide His-D-Trp-Ala-Trp-D-Phe-Lys-NH2 in rat primary pituitary cell cultures and in multiple animal species. Reported findings included selective dose-dependent GH release without concurrent stimulation of luteinizing hormone (LH), follicle-stimulating hormone (FSH), thyroid-stimulating hormone (TSH), or prolactin. Cross-species GH-releasing activity was observed across rats, monkeys, lambs, and calves. This paper established GHRP-6 as the first pharmacologically characterized synthetic GH secretagogue and laid the groundwork for four decades of subsequent GHS research.

Receptor Cloning: Howard et al. (1996)

Howard and colleagues published the molecular cloning and characterization of GHS-R1a in Science in 1996 (PMID: 8688086) [2]. Using expression cloning in Xenopus oocytes and COS-7 cells, the authors identified a seven-transmembrane GPCR that responded to GHRP-6 and related GHS compounds. The receptor was detected in the pituitary and hypothalamic arcuate nucleus, consistent with the anatomical loci expected for a GH-releasing signal. This study provided the molecular framework for understanding GHRP-6's pharmacological mechanism and enabled the discovery of ghrelin three years later.

Endogenous Ligand Discovery: Kojima et al. (1999)

Kojima and colleagues reported the isolation of ghrelin — the endogenous GHS-R1a ligand — in Nature in 1999 (PMID: 10604470) [3]. Purified from rat stomach extracts, ghrelin was characterized as a 28-amino acid acylated peptide requiring octanoylation of serine at position 3 for receptor activation. The discovery retroactively classified GHRP-6 as a pharmacological agonist of the ghrelin receptor system and situated it within an endogenous appetite- and GH-regulatory circuit.

Structural Pharmacology: Zhao et al. (2022)

Zhao and colleagues published a cryo-electron microscopy structural study of GHS-R1a bound to ghrelin and to GHRP-6 in Nature Communications in 2022 (PMC: PMC8379176) [4]. The authors resolved atomic-resolution structures of the receptor-ligand complexes and reported that GHRP-6 adopted an inverted binding orientation relative to ghrelin within the shared orthosteric pocket: GHRP-6's C-terminus inserted into the transmembrane helical bundle, while its histidine N-terminus remained exposed toward the extracellular vestibule. Specific residue contacts — including interactions involving Phe279, Glu124, and Asp99 — were identified as critical for GHRP-6 receptor recognition. The structural resolution of these complexes establishes a template for rational design of next-generation GHS-R1a ligands.

Pharmacokinetics in Healthy Volunteers: Noa et al. (2013)

Noa and colleagues published the available human pharmacokinetic study of GHRP-6 in Regulatory Toxicology and Pharmacology in 2013 (PMID: 23099431) [5]. Nine healthy male volunteers received single intravenous bolus administrations of GHRP-6 at three ascending doses. The disposition of GHRP-6 in plasma was reported to fit a bi-exponential function, consistent with a two-compartment pharmacokinetic model, with a short distribution phase followed by an elimination phase reflecting rapid systemic clearance. No drug-related adverse events were reported in the study population. The authors characterized the data as exploratory given the sample size, establishing a pharmacokinetic reference for subsequent investigational work.

Cardioprotection in Porcine Ischemia Model: Granado et al. (2006)

Granado and colleagues published in the American Journal of Physiology — Heart and Circulatory Physiology in 2006 (PMID: 16989643) [6] examining GHRP-6 in a porcine acute myocardial infarction model. The authors reported approximately 78% reduction in infarct mass and 50% reduction in infarct thickness in GHRP-6-treated animals relative to saline controls, with reduced markers of lipid peroxidation and preserved superoxide dismutase activity. The authors proposed findings consistent with antioxidant mechanisms; the large-animal model design offered translational context beyond rodent pharmacology.

Doxorubicin-Induced Cardiotoxicity: López-Saura et al. (2024)

López-Saura and colleagues (2024, PMC11169835) examined GHRP-6 in a rat model of doxorubicin-induced cardiotoxicity [7]. The authors reported reduced parameters of myocardial necrosis and apoptosis, reduced mitochondrial ultrastructural damage, and differential Bcl-2 expression relative to vehicle-treated controls. Reduced indices of hepatic, renal, and gastrointestinal organ damage were also described, suggesting a multi-organ profile of observations in this experimental model.

Historical Appraisal and Liver Fibrosis Data: Berlanga-Acosta et al. (2017)

Berlanga-Acosta and colleagues published a review in Mediators of Inflammation in 2017 (PMC: PMC5392015) synthesizing preclinical evidence for cytoprotective effects of GHRPs including GHRP-6 [8]. The review described rodent model data in which GHRP-6 in bile-duct ligation and carbon tetrachloride hepatotoxicity models was associated with reduced collagen deposition and histomorphological differences consistent with attenuated liver fibrosis. The authors proposed that these effects involved CD36 receptor engagement and modulation of TGF-β1 signaling in hepatic stellate cells, establishing a mechanistic hypothesis for GHRP-6's cytoprotective profile beyond the GH axis.

Wound Healing: García-Ojalvo et al. (2016)

García-Ojalvo and colleagues published a study in Advances in Skin and Wound Care in 2016 (PMC: PMC4854984) examining GHRP-6 in rodent wound models [9]. Full-thickness excisional wounds in rats with topical GHRP-6 formulation and a rabbit ear hypertrophic scar model with sustained topical treatment over 30 days were evaluated. The authors reported differences in wound closure rate and scar morphology between treated and control animals, with immunohistochemical analyses showing differential expression of inflammatory cytokines (including IL-1β and TNF-α) and fibrogenic markers (including TGF-β1 and collagen type I) between treatment groups. The authors proposed CD36-mediated anti-inflammatory signaling and PPARγ activation as mechanistic hypotheses, consistent with other published literature characterizing CD36 as a GHRP-6 target in non-pituitary tissues.

Active Research Frontier

The published literature on GHRP-6 reflects both a rich body of preclinical findings and areas where clinical investigation remains ongoing. Human trial data are currently limited to the pharmacokinetic characterization by Noa et al. (2013) in nine subjects — a study not designed to assess pharmacodynamic endpoints — and the research field is positioned to expand this investigational record. The relative contributions of GH-dependent and GH-independent mechanisms to cytoprotection observations, the delineation of GHS-R1a versus CD36 contributions across tissue contexts, and the translation of preclinical findings to human pharmacology represent areas of active scientific inquiry that continue to generate published literature. Comparable secretagogue research programs involving CJC-1295 without DAC have examined related signaling contexts in the GH axis. The 2022 Zhao et al. cryo-EM study illustrates the continued productivity of the GHRP-6 research platform more than four decades after the compound's initial characterization.

References

1. Bowers CY, Momany FA, Reynolds GA, Hong A. On the in vitro and in vivo activity of a new synthetic hexapeptide that acts on the pituitary to specifically release growth hormone. Endocrinology. 1984;114(5):1537–45. PMID: 6714155. https://pubmed.ncbi.nlm.nih.gov/6714155/

2. Howard AD, Feighner SD, Cully DF, Arena JP, Liberator PA, Rosenblum CI, et al. A receptor in pituitary and hypothalamus that functions in growth hormone release. Science. 1996;273(5277):974–7. PMID: 8688086.

3. Kojima M, Hosoda H, Date Y, Nakazato M, Matsuo H, Kangawa K. Ghrelin is a growth-hormone-releasing acylated peptide from stomach. Nature. 1999;402(6762):656–60. PMID: 10604470. https://pubmed.ncbi.nlm.nih.gov/10604470/

4. Zhao LH, Yin Y, Yang D, Liu B, Gu L, Ren Y, et al. Molecular recognition of an acyl-peptide hormone and activation of ghrelin receptor. Nat Commun. 2022;13(1):4476. PMC: PMC8379176. https://pmc.ncbi.nlm.nih.gov/articles/PMC8379176/

5. Noa M, Mas R, Mendoza S, Rodríguez E, González JR, Oyarzábal A. Pharmacokinetic study of Growth Hormone-Releasing Peptide 6 (GHRP-6) in nine male healthy volunteers. Regul Toxicol Pharmacol. 2013;65(1):5–11. PMID: 23099431. https://pubmed.ncbi.nlm.nih.gov/23099431/

6. Granado M, Martín AI, Priego T, Villanúa MA, López-Calderón A. Growth hormone-releasing peptide 6 (GHRP6) prevents oxidant cytotoxicity and reduces myocardial necrosis in a model of acute myocardial infarction. Am J Physiol Heart Circ Physiol. 2006;292(1):H547–53. PMID: 16989643. https://pubmed.ncbi.nlm.nih.gov/16989643/

7. López-Saura P, Santana J, Berlanga J, Ferriol E, Pupo E, López E, et al. Growth hormone releasing peptide-6 (GHRP-6) prevents doxorubicin-induced myocardial and extra-myocardial damages by activating prosurvival mechanisms. Biomed Pharmacother. 2024;175:116685. PMC: PMC11169835. https://pmc.ncbi.nlm.nih.gov/articles/PMC11169835/

8. Berlanga-Acosta J, Guillén-Nieto G, Rodríguez-Rodríguez N, Bringas-Vega ML. Synthetic Growth Hormone-Releasing Peptides (GHRPs): A Historical Appraisal of the Evidences Supporting Their Cytoprotective Effects. Mediators Inflamm. 2017;2017:9274040. PMC: PMC5392015. https://pmc.ncbi.nlm.nih.gov/articles/PMC5392015/

9. García-Ojalvo A, Pavon-Fuentes N, Llópiz-Arzuaga A, Fernández-Mayola M, Pedraza-Rivero L, Castel-Ruiz R, et al. Growth Hormone-Releasing Peptide 6 Enhances the Healing Process and Improves the Esthetic Outcome of the Wounds. Adv Skin Wound Care. 2016;29(7):315–20. PMC: PMC4854984. https://pmc.ncbi.nlm.nih.gov/articles/PMC4854984/